Caliper's $46 Mil. IPO To Fund LabChip Manufacturing Scale-Up, R&D
This article was originally published in The Gray Sheet
Executive Summary
Development of "lab-on-a-chip" technologies used in high-throughput nucleic acid analysis for diagnostics applications is one of several development projects that would benefit from Caliper Technologies' $46 mil. initial public offering.
You may also be interested in...
Caliper Technologies Corp
Initial public offering of 4.5 mil. shares at $16 each grosses $72 mil. Larger than the previously anticipated 3.6 mil. shares at $13-15 each, the IPO will help fund scale-up of manufacturing operations for initial LabChip "lab-on-a-chip" technologies and further R&D activities (1"The Gray Sheet" Dec. 6, p. 16). The Mountain View, California firm's stock is trading under the symbol "CALP," and not "CLPR" as expected earlier. Credit Suisse First Boston, CIBC World Markets Corp. and Hambrecht & Quist LLC were underwriters for the offering
Caliper Technologies Corp
Initial public offering of 4.5 mil. shares at $16 each grosses $72 mil. Larger than the previously anticipated 3.6 mil. shares at $13-15 each, the IPO will help fund scale-up of manufacturing operations for initial LabChip "lab-on-a-chip" technologies and further R&D activities (1"The Gray Sheet" Dec. 6, p. 16). The Mountain View, California firm's stock is trading under the symbol "CALP," and not "CLPR" as expected earlier. Credit Suisse First Boston, CIBC World Markets Corp. and Hambrecht & Quist LLC were underwriters for the offering
Sequenom IPO Prospectus Shows Diagnostics Potential In Product Pipeline
Potential applicability of Sequenom, Inc.' s industrial genomics technology to the field of diagnostics is outlined in a preliminary prospectus for an initial public offering of up to $70 mil. in common stock, recently filed with the Securities and Exchange Commission.